# An Individualized Anti-Cancer Vaccine Study in Patients With HCC

> **NCT01995227** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Mirror Biologics, Inc.**

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** AlloVax
- **BIOLOGICAL:** CRCL
- **BIOLOGICAL:** AlloStim

## Key facts

- **NCT ID:** NCT01995227
- **Lead sponsor:** Mirror Biologics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-12
- **Primary completion:** 2018-02
- **Final completion:** 2018-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study site change to Thailand
- **Last updated:** 2020-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01995227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01995227, "An Individualized Anti-Cancer Vaccine Study in Patients With HCC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01995227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*